Yifan Pharmaceutical Co., Ltd. (002019.SZ) has a MoatMap StockRank of 38/100 based on Quality (52/100), Value (36/100), and Momentum (37/100) factor scores. The current signal is HOLD. Yifan Pharmaceutical lacks a global economic moat and faces severe domestic pricing pressure from China's volume-based procurement (VBP) policy, leading to low and volatile ROIC.
Yifan Pharmaceutical Co., Ltd. develops and manufactures active pharmaceutical ingredients (APIs), generic drugs, and innovative biologics. The company is a global leader in Vitamin B5 production and a pioneer in bringing Chinese-developed biologics to international markets. It operates as a globally integrated pharmaceutical player with a strong pipeline of innovative therapies.
| Price | $1.47 |
| Market Cap | $1.9B |
| P/E (TTM) | 34.59 |
| P/E (Forward) | 16.44 |
| Price/Book | 1.37 |
| Return on Equity | 3.8% |
| Return on Invested Capital | 4.9% |
| Debt/Equity | 27.11 |
| Gross Margin | 46.2% |
| Operating Margin | 11.8% |
| Revenue Growth | -5.4% |
| Dividend Yield | 1.0% |
| Free Cash Flow | $-4M |
Yifan Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - General industry, part of the Healthcare sector (China).